The 64th Congress of the American Society of Hematology (ASH) was a great success in terms of attendance in December 2022, with over 30,000 participants and 4,000 abstracts presented. APLUSA was exhibiting in person, and our on-site team was able to see for themselves just how busy it was.
Our Social Media Listening team had already shared an analysis of the “hot” impact of the conference on social networks. You can find it here.
We have now completed this analysis with a survey of 50 French haematologists and haemato-oncologists to identify the news they remembered a month and a half after the event, and measure its potential impact on practice.
Objectives and method
50 self-administered Internet questionnaires recruited from the APLUSA panel.
50 oncologists and hematologists involved in hematological cancers.
3 to 5 mn
Date of fieldwork: January 17, 2023 to February 1, 2023
Some results
The annual ASH congress is proving to be an unmissable event in hematology whose informational reach goes far beyond the face-to-face setting, capturing and informing nearly all the physicians surveyed this year:
Awareness of information/communications presented at the ASH 2022 Congress (December 10 to 13, 2022):
NB: The study fieldwork after ASH 2019 took place between 10 and 30 days after the event; the study fieldwork after ASH 2022 gave doctors a little more time = between 30 and 45 days after the event, which may also explain why they were exposed to later reports.
Main media and means of communication used to gather information presented at the ASH 2022 congress:
In addition to attracting a very large audience, the ASH meeting has a major impact on changing practices, whatever the world of access to information.
A major informational impact, with more than 8 out of 10 doctors saying they were ready to modify their therapeutic strategies following the ASH 2022 presentations:
Therapeutic news highlights in phase with practitioners’ activities:
And that’s not all…
Complete the form below to find out about the main treatments remembered, the most frequently mentioned laboratories, focus on CAR-T, YESCARTA, bispecifics, TECVAYLI, TALQUETAMAB, IBTK & IBCL2, IMBRUVICA, IMBRUVICA + VENCLYXTO, BRUKINSA, VENCLYXTO, anti-CD38 – DARZALEX…
